This Article Full Text Full Text (PDF) All Versions of this Article: 38/6/1952    most recent STROKEAHA.106.479477v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yip, T. R. Articles by Demaerschalk, B. M. Search for Related Content PubMed PubMed Citation Articles by Yip, T. R. Articles by Demaerschalk, B. M. Related Collections Thrombolysis Related Article

(Stroke. 2007;38:1952.)
© 2007 American Heart Association, Inc.

Research Letters

Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada

Todd R. Yip, MD, MSc Bart M. Demaerschalk, MD, MSc, FRCPC

From Department of Physical Medicine and Rehabilitation (T.R.Y.), University of Saskatchewan, Saskatoon, SK, Canada; Department of Neurology (B.M.D.), Mayo Clinic, Scottsdale, Ariz.

Correspondence to Bart M. Demaerschalk, MD, Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259. E-mail demaerschalk.bart{at}mayo.edu

Abstract

Background and Purpose— Intravenous tissue plasminogen activator (tPA) is an economically worthwhile but underused treatment option for acute ischemic stroke. We sought to identify the extent of tPA use in Canadian medical centers and the potential savings associated with increased use nationally and by province.

Methods— We determined the nationwide annual incidence of ischemic stroke from the Canadian Institute of Health Information. The proportion of all ischemic stroke patients who received tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of a universal health care system during 1 year. We estimated cost-savings with incrementally (eg, 2%, 4%, 6%, 8%, 10%, 15%, and 20%) increased use of tPA for acute ischemic stroke nationally and provincially.

Results— The current average national tPA utilization is 1.4%. For every increase of 2 percentage points in utilization, $757 204 (Canadian) could possibly be saved annually (95% CI maximum loss of $3 823 992 to a maximum savings of $2 201 252). With a 20% rate, >$7.5 million (Canadian) could be saved nationwide the first year.

Conclusions— We estimate that even small increases in the proportion of all Canadian ischemic stroke patients receiving tPA could result in substantial realized savings for Canada’s health care system.

Key Words: acute ischemic • costs • economics • medical • stroke • thrombolysis • tissue plasminogen activator

Related Article:

The Economics of Thrombolysis

Michael D. Hill and Mukul Sharma
Stroke 2007 38: 1732-1733. [Full Text] [PDF]